Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Dezember 2023 11:02 ET | Quelle: Celcuity Inc.

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an...
22. November 2023 08:05 ET | Quelle: Celcuity Inc.

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
13. November 2023 07:05 ET | Quelle: Celcuity Inc.

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
06. November 2023 07:30 ET | Quelle: Celcuity Inc.

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...